Compare Crispr Therapeutics AG (CRSP) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs NetEase Inc — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while NetEase Inc trades at $129.23 (market cap $82.39B). The key difference: NetEase Inc is far larger — about 16.6× Crispr Therapeutics AG's market cap, and NetEase Inc pays a 2.35% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NTES | |
|---|---|---|
Market Cap | $4.97B | $82.39B |
Sector | Health | Media |
52-Week High | $76.78 | $159.34 |
52-Week Low | $44.34 | $109.26 |
Enterprise Value | $3.32B | $58.86B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
NTES trades at $131.43, up 2.66% today, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.84% net income margin and 22.12% ROE. Recent Q1 2026 earnings beat expectations at $2.53 EPS versus $2.19 forecast. Analyst sentiment is overwhelmingly positive with 82% buy ratings. Cash flow from operations surged to $50.74B in 2025, though net cash flow was negative due to heavy investing activities.
Outlook remains favorable given earnings momentum, international expansion in gaming, and attractive valuation at 16.89 P/E. Risks include reliance on Chinese market and competitive pressures. Wall Street sees 34.7% upside potential based on price targets, supporting a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
